The Effect of Beta-glucan in Non-Small Cell Lung Cancer

Part of paid clinical trials in Louisville, Kentucky.

Sponsor
University of Louisville
Study ID
NCT00682032
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • beta-glucan — DIETARY_SUPPLEMENT
    AIM 2: regimen to begin after baseline blood draw; AIM 3: regimen to begin after baseline blood draw and to be completed prior to surgery

Study Details

The purpose of this study is to determine how beta-glucan affects the immune system in subjects with non-small cell lung cancer.

Key Dates

Start date
Oct 31, 2008
Status verified
Jan 2025
Primary completion
Apr 30, 2025
Completion
Mar 31, 2029

Study Design

Enrollment
300 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: AIM 2: subjects with suspected or definitive NSCLC diagnosis
    1 (one) 250mg beta-glucan capsule 3 times a day for 14 days
  • Experimental: AIM 3: subjects with resectable NSCLC
    1 (one) 250mg beta-glucan capsule 3 times a day for 10 to 20 days

Primary Outcome Measure

blood specimens will be obtained to examine the ability of beta-glucan to prime neutrophils complement receptor 3 (CR3) and test the cytotoxicity of the primed neutrophils. [ Time Frame: pre-treatment and post-treatment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
James Graham Brown Cancer CenterLouisvilleKentucky40202
Goetz H Kloecker, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Louisville, KY

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
James Graham Brown Cancer Center· Louisville, KY

Related Studies